Clinical Scorecard: Determinants of Brain Metastasis Development and Survival in Breast Cancer Patients: Insights from a Multi-Center Study
At a Glance
Category
Detail
Condition
Breast cancer with brain metastases (BCBM)
Key Mechanisms
Breast cancer subtypes, brain metastasis development, and treatment modalities including surgery, radiotherapy, chemotherapy, and targeted therapies influence survival outcomes.
Target Population
Patients with pathologically confirmed breast cancer and brain metastases diagnosed between 2010 and 2020.
Care Setting
Multicenter clinical oncology settings with access to multimodal treatments including surgery, radiotherapy, systemic chemotherapy, and targeted therapies.
Key Highlights
Brain metastases occur in 20%-40% of breast cancer patients and are associated with poor survival, especially in triple negative subtype with median OS <5 months.
Multimodal treatment including surgery, whole brain radiotherapy, stereotactic radiosurgery, systemic chemotherapy, and novel targeted therapies improves survival outcomes.
The Breast Graded Prognostic Assessment (Breast-GPA) tool incorporating receptor subtype, age, performance status, and extracranial metastases aids survival prediction and treatment decisions.
Guideline-Based Recommendations
Diagnosis
Confirm breast cancer diagnosis by pathology (biopsy or surgical specimen).
Confirm brain metastases by CT or MRI imaging.
Assess tumor receptor status (HR, HER2) and performance status (KPS, ECOG).
Use targeted therapies including monoclonal antibodies, tyrosine kinase inhibitors (TKIs), PARP inhibitors, CDK4/6 inhibitors, and immune checkpoint inhibitors (ICIs) as appropriate.
Employ capecitabine as a category 2B systemic chemotherapy option for BCBM.
Distinguish between initial and late treatments post brain metastasis development for tailored therapy.
Monitoring & Follow-up
Monitor overall survival from time of brain metastasis diagnosis.
Use prognostic tools such as Breast-GPA to guide treatment and follow-up.
Track extracranial metastases and performance status changes.
Risks
Brain metastases confer poor prognosis with variable survival influenced by tumor subtype and treatment.
Triple negative breast cancer patients have disproportionately shorter survival.
Late development of brain metastases indicates disease progression requiring treatment adjustment.
Patient & Prescribing Data
318 patients with breast cancer and confirmed brain metastases from 2010 to 2020.
Majority received chemotherapy (86.5%), breast surgery (92.5%), and radiotherapy (62.9%). Targeted therapies included HER2-targeted agents (29.9%), immunotherapy (11%), PARP inhibitors (8.5%), CDK4/6 inhibitors (27.4%), and TKIs (19.8%). After recurrence, late treatments included chemotherapy (43.4%), late endocrine therapy (34.3%), and late HER2-targeted therapy (25.8%).
Clinical Best Practices
Utilize Breast-GPA scoring incorporating receptor subtype, age, KPS, and extracranial metastases for prognostication.
Adopt a multimodal approach combining local (surgery, radiotherapy) and systemic therapies including novel targeted agents.
Differentiate treatment strategies before and after brain metastasis development to optimize outcomes.
Regularly assess performance status and extracranial disease burden to guide treatment decisions.
by Ahmad Alhalabi, Theresa Abdo, Ali Hijazi, Mohamed Mohanna, Rami Tfayli, María Herrán, Saad Sabbagh, Saffet Guleryuz, Razan Mohanna, Rashid Mahrous, Kaylee Sarna, Surabhi Ranjan, Christopher W Fleming, Zeina Nahleh
